NMRA · Neumora Therapeutics Inc
United States · RS rating 15 · As of 2026-11-03
| Price | 0.57 USD |
|---|---|
| 1-day change | +15.1% |
| RS rating (overall / 1M / 3M / 12M) | 15 / 80 / 5 / 9 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 23 / 13 / 25 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +0.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +84.1% |
| Market cap (USD) | $407.4M |